Quest Diagnostics Incorporated
DGXHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeQuest Diagnostics Incorporated provides diagnostic testing and services in the United States. With a market capitalization of $21.38B, it sits in large-cap territory. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Market Cap
$21.38B
Beta
0.59
P/E (TTM)
21.32
P/E (Fwd)
16.55
EPS (TTM)
$9.06
EPS (Fwd)
$11.67
ROE
14.5%
ROA
6.3%
Cash
$393.0M
Total Debt
$6.41B
Free CF
$947.9M
52W Change
11.1%
Annual Financials
Cash vs Debt
Quest Diagnostics Incorporated carries $6.41B in total debt against $393.0M in cash reserves — debt is roughly 16.3x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow comes in at $947.9M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 14.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $9.88B to $11.04B.
The relatively low beta of 0.59 suggests DGX is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DGX.